Z
Zhuhai Beston Technology
A company developing cell therapy and gene therapy products
About Zhuhai Beston Technology
Operating at the forefront of genetic medicine, Base Therapeutics is a clinical-stage biopharmaceutical company established in 2021. The company was co-founded by former Baylor medical school classmates Dr. Huang Xingxu and Dr. Xu Tianhong, who now serves as CEO. The founding team merges scientific acumen with industry leadership, including highly cited scientists in the gene-editing field and seasoned entrepreneurs.
The firm is centered on developing therapies for cancer and genetic diseases through next-generation gene editing technologies, specifically base editing and prime editing. Base editing is a precise method of altering a single nucleotide in the DNA sequence without making a double-stranded break, which reduces the risk of unintended mutations compared to traditional CRISPR-Cas9 methods. The company's core technology is its proprietary AccuBase® base editing system, a protein-based platform that enables highly efficient gene editing with what the company describes as zero off-target effects. This system, for which Base Therapeutics has global freedom to operate (FTO) and multiple patents, is designed for both in-vitro and in-vivo applications.
Base Therapeutics' business model involves both internal pipeline development and strategic collaborations. The company generates revenue by licensing its AccuBase® technology to other pharmaceutical companies for use in their respective fields, including CAR-T therapies. Its internal pipeline is focused on developing off-the-shelf, universal cell therapies. A lead candidate is NK510, a base-edited Natural Killer (NK) cell product designed to treat solid tumors. In late 2024, NK510 received Investigational New Drug (IND) approvals from both the U.S. FDA and China's NMPA, a significant milestone marking the first base-edited NK cell therapy to enter clinical trials. The company also has other products in development, including treatments for hematological malignancies and autoimmune diseases, and explores applications in agriculture.
Headquartered in Shanghai, the company has established a substantial infrastructure, including a 2,500-square-meter GMP-compliant manufacturing facility to support clinical trials and production. With backing from top-tier biopharma investors like Gobi Partners and Baidu Ventures, Base Therapeutics has secured significant funding through Seed and Series A rounds to advance its research, clinical trials, and international expansion, with a focus on the Greater Bay Area via its Hong Kong office.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2024 | $2.8M | $100M | Gobi Ventures | ↗ |
| SERIES A✓Equity / VC | Jan 2023 | $20M | $80M | Honghui Capital · Broad Huitong · Spark Ventures · Baidu Ventures | ↗ |
Growth signals
Latest recorded traffic for Zhuhai Beston Technology is 960 monthly website visits, up 357.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhuhai Beston Technology in its local ecosystem
The Zhuhai Beston Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- HCHonghui Capital
- BHBroad Huitong
- SVSpark Ventures
Baidu Ventures
Xinxi Capital- GVGreat Eagle VC
- GVGobi Ventures
Other known investors1 additional known investor
Gobi Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhuhai Beston Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhuhai Beston Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









